Anderlini P, Chan F A, Champlin R E, Körbling M, Strom S S
Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4095, USA.
Bone Marrow Transplant. 2002 Nov;30(10):661-3. doi: 10.1038/sj.bmt.1703693.
Data on the long-term safety of filgrastim administration in peripheral blood progenitor cell (PBPC) donors are scarce. The main theoretical risk is believed to be the possible development of leukemia. We conducted a survey of filgrastim-treated related donors to determine the incidence of leukemia after PBPC donation. Of the 343 PBPC donors eligible for inclusion in the survey, 281 (82%) were interviewed by telephone between December 1998 and February 2000. The mean age at donation was 44 years. The median time elapsed after PBPC donation was 39 months, and in 278 (99%) of the interviewed donors it was at least 1 year. At the time of the interview none of the donors had been diagnosed with acute or chronic leukemia. Although the sample size is small and the follow-up duration is limited, these data suggest that exposure to filgrastim is not associated with any notable risk of leukemia development in PBPC donors.
关于外周血祖细胞（PBPC）供体使用非格司亭的长期安全性数据稀缺。主要的理论风险被认为是白血病的可能发生。我们对接受非格司亭治疗的相关供体进行了一项调查，以确定PBPC捐献后白血病的发病率。在343名符合纳入调查条件的PBPC供体中，281名（82%）在1998年12月至2000年2月期间接受了电话访谈。捐献时的平均年龄为44岁。PBPC捐献后的中位时间为39个月，在278名（99%）接受访谈的供体中，这一间隔至少为1年。在访谈时，没有一名供体被诊断出患有急性或慢性白血病。尽管样本量小且随访时间有限，但这些数据表明，PBPC供体接触非格司亭与白血病发生的任何显著风险无关。
